A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
first 100 days (p \0.001), and improved 2 year survival rates (70% p 5 0.03). Our data suggest that etanercept effectively reduces TNFR1 levels at day 7 post-HCT, which has previously been correlated with transplant outcomes. The median day 7 TNFR1 levels were statistically different across conditioning regimens, and those with low TNFR1 levels had improved outcomes (FluBu4 . BCNU/Busulfan . TBI). The combination of FluBu4 with etanercept as a promising regimen for high-risk allogeneic HCTdoi:10.1016/j.bbmt.2009.12.022 fatcat:7nhsipd5grenbfbck4v6iw7wja